Fubotv earnings beat by $0.10, revenue topped estimates
Akero Therapeutics, Inc. (NASDAQ:AKRO), a $4.35 billion market cap biotech company whose stock has surged 133% over the past year, reported that Chief Scientific Officer Timothy Rolph sold 1,129 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price ranging from $54.33 to $54.84, netting Rolph approximately $61,914.
Following the transaction, Rolph directly owns 166,234 shares of Akero Therapeutics. The sale was to cover tax withholding obligations related to the vesting of restricted stock units, as per the company’s "sell-to-cover" policy.
In other recent news, Akero Therapeutics has reported promising results from its Phase 2b SYMMETRY trial, indicating that their drug efruxifermin (EFX) may improve liver fibrosis in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The trial results, published in the New England Journal of Medicine, highlighted significant improvements in fibrosis without worsening MASH in treated patients compared to the placebo group. Akero’s financial standing remains strong, with $1.1 billion in cash reserves, projected to support operations into 2028. Analysts have been active in updating their outlooks on Akero, with Jefferies maintaining a Buy rating and a $75 price target, while Citi and Morgan Stanley (NYSE:MS) made slight downward adjustments to their targets to $78 and $84, respectively, but still recommend buying the stock. Clear Street initiated coverage with a Buy rating and a $49 target, noting the "best-in-class potential" of EFX for various stages of liver disease. Akero’s ongoing Phase 3 SYNCHRONY program is being closely watched, with results anticipated in the first half of 2027. The company continues to explore the potential of EFX in treating different stages of MASH, a condition with no currently approved treatments. These developments underscore Akero’s active role in advancing liver disease therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.